News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
522,159 Results
Type
Article (44505)
Company Profile (122)
Press Release (477532)
Section
Business (144831)
Career Advice (2393)
Deals (27917)
Drug Delivery (113)
Drug Development (67889)
Employer Resources (148)
FDA (15591)
Job Trends (11939)
News (263439)
Policy (29583)
Tag
Academia (2282)
Alliances (35887)
Alzheimer's disease (1348)
Antibody-drug conjugate (ADC) (107)
Approvals (15519)
Artificial intelligence (167)
Bankruptcy (302)
Best Places to Work (9179)
Breast cancer (199)
Cancer (1497)
Cardiovascular disease (127)
Career advice (1996)
CAR-T (110)
Cell therapy (313)
Clinical research (54467)
Collaboration (518)
Compensation (312)
COVID-19 (2570)
C-suite (131)
Data (1390)
Diabetes (193)
Diagnostics (5152)
Drug pricing (110)
Earnings (57417)
Employer resources (136)
Events (75589)
Executive appointments (464)
FDA (16384)
Funding (457)
Gene therapy (231)
GLP-1 (703)
Government (3818)
Healthcare (14762)
Infectious disease (2670)
Inflammatory bowel disease (108)
Interviews (445)
IPO (13905)
Job creations (3154)
Job search strategy (1662)
Layoffs (471)
Legal (6927)
Lung cancer (223)
Manufacturing (210)
Medical device (11110)
Medtech (11113)
Mergers & acquisitions (14279)
Metabolic disorders (551)
Neuroscience (1728)
NextGen: Class of 2025 (4979)
Non-profit (3161)
Northern California (1760)
Obesity (324)
Opinion (199)
Patents (137)
People (42197)
Phase I (16286)
Phase II (23580)
Phase III (19379)
Pipeline (629)
Postmarket research (2204)
Preclinical (6550)
Radiopharmaceuticals (205)
Rare diseases (302)
Real estate (4250)
Regulatory (20506)
Research institute (2052)
Resumes & cover letters (401)
Southern California (1484)
Startups (2739)
United States (15137)
Vaccines (656)
Weight loss (252)
Date
Today (142)
Last 7 days (522)
Last 30 days (2326)
Last 365 days (31106)
2025 (2326)
2024 (31407)
2023 (34982)
2022 (45057)
2021 (48498)
2020 (45512)
2019 (36210)
2018 (27397)
2017 (27804)
2016 (25804)
2015 (27973)
2014 (21774)
2013 (17791)
2012 (18963)
2011 (19382)
2010 (17504)
Location
Africa (667)
Arizona (147)
Asia (30755)
Australia (5392)
California (3934)
Canada (1181)
China (290)
Colorado (175)
Connecticut (205)
Europe (74643)
Florida (581)
Georgia (133)
Illinois (341)
Indiana (194)
Maryland (652)
Massachusetts (3041)
Michigan (148)
Minnesota (262)
New Jersey (1121)
New York (1096)
North Carolina (728)
Northern California (1760)
Ohio (130)
Pennsylvania (888)
South America (1033)
Southern California (1484)
Texas (559)
Washington State (394)
522,159 Results for "symphogen a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.
January 22, 2025
·
2 min read
·
Tristan Manalac
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
Neurodegenerative disease
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.
January 30, 2025
·
2 min read
·
Tristan Manalac
NextGen
BioSpace
’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
·
5 min read
·
Heather McKenzie
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
Deals
Servier Completes the Acquisition of Symphogen
Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier’s antibody center of excelle
June 4, 2020
·
2 min read
Parkinson’s disease
Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial
The report comes just two days after Novartis announced its own Parkinson’s drug failure.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Business
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”
January 15, 2025
·
1 min read
·
Heather McKenzie
CAR-T
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.
December 10, 2024
·
2 min read
·
Tristan Manalac
Accelerated approval
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, Sarepta’s Exondys and Covis’ Makena.
January 15, 2025
·
2 min read
·
Tristan Manalac
1 of 52,216
Next
